Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma

So Young Yoo; Narayanasamy Badrinath; Hyun Young Woo; Jeong Heo

doi:10.1155/2017/5198798

Mediators of Inflammation (Jan 2017)

Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma

So Young Yoo,
Narayanasamy Badrinath,
Hyun Young Woo,
Jeong Heo

Affiliations

So Young Yoo: BIO-IT Foundry Technology Institute, Pusan National University, Busan 46241, Republic of Korea
Narayanasamy Badrinath: BIO-IT Foundry Technology Institute, Pusan National University, Busan 46241, Republic of Korea
Hyun Young Woo: Department of Internal Medicine, College of Medicine, Pusan National University and Medical Research Institute, Yangsan 50612, Republic of Korea
Jeong Heo: Department of Internal Medicine, College of Medicine, Pusan National University and Medical Research Institute, Yangsan 50612, Republic of Korea

DOI: https://doi.org/10.1155/2017/5198798
Journal volume & issue: Vol. 2017

Abstract

Read online

Hepatocellular carcinoma is highly refractory cancer which is resistant to conventional chemotherapy and radiotherapy, carrying a dismal prognosis. Although many anticancer drugs have been developed for treating HCC, sorafenib is the only effective treatment, but it only prolongs survival duration for about 3 months. Recently, oncolytic virotherapy has shown promising results in treating HCCs and the effects can be more enhanced by adopting immune modulatory molecules. This review discusses the current status of treating HCC and the effective strategy of oncolytic virus-based immunotherapy for the treatment of HCCs.

Published in Mediators of Inflammation

ISSN: 0962-9351 (Print); 1466-1861 (Online)
Publisher: Hindawi Limited
Country of publisher: United Kingdom
LCC subjects: Medicine: Pathology
Website: https://www.hindawi.com/journals/mi/

About the journal